CEO [CNOOC] 6-K: (Original Filing)
[CNOOC Limited Jiewen Li]
CEO [CNOOC] 6-K: CNOOC Limited Jiewen Li
[CNOOC Limited Jiewen Li]
CHA [CHINA TELECOM] 6-K: (Original Filing)
[Page 1.1 Announcement in relation to appointments of Chairman and Chief Executive Officer as well as President and Chief Operating Officer, dated April 25, 2016 A-1 our business and operating strategies and our ability to successfully execute these strategies; our network expansion and capital expenditure plans; our operations and business prospects; the expected benefit of any]
CHA [CHINA TELECOM] 6-K: Page 1.1 Announcement in relation to appointments of
[Page 1.1 Announcement in relation to appointments of Chairman and Chief Executive Officer as well as President and Chief Operating Officer, dated April 25, 2016 A-1 our business and operating strategies and our ability to successfully execute these strategies; our network expansion and capital expenditure plans; our operations and business prospects; the expected benefit of any]
SVA [SINOVAC BIOTECH] 20-F: (Original Filing)
[Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 56,906,561 common shares as of December 31, 2015 ¨ x ¨ x x ¨ x ¨ o Large accelerated filer x Accelerated filer o Non-accelerated filer x U.S. GAAP International Financial] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Sinovac Biotech Co., Ltd., a PRC company 3. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 4. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company 5. Sinovac Biomed Co., Ltd. (formerly known as Sinovac Zhong] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER I, Nan Wang, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Weidong Yin Chief Executive Officer] [CERTIFICATION BY THE CHIEF FINANCIAL OFFICER (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Nan Wang Chief Financial Officer] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the following Registration Statements: i) Registration Statement (Form S-8 No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan; and ii) Registration Statement (Form S-8 No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan; of our reports dated April 25, 2016, with]
BABA [Alibaba] 6-K: (Original Filing)
[Alibaba Group Announces the Results of a Non-Disciplinary Review by the Hong Kong Takeovers and Mergers Panel The Hong Kong Takeovers and Mergers Panel (the Panel) ruled on April 23, 2016 in a non-disciplinary review of Alibaba Groups 2014 investment into CITIC 21CN Company Limited (HKSE stock code: 241), which was re-named Alibaba Health Information Technology Limited (Alibaba Health), that] [2 ALIBABA GROUP HOLDING LIMITED]
BABA [Alibaba] 6-K: Alibaba Group Announces the Results of a Non-Disciplinary
[Alibaba Group Announces the Results of a Non-Disciplinary Review by the Hong Kong Takeovers and Mergers Panel The Hong Kong Takeovers and Mergers Panel (the Panel) ruled on April 23, 2016 in a non-disciplinary review of Alibaba Groups 2014 investment into CITIC 21CN Company Limited (HKSE stock code: 241), which was re-named Alibaba Health Information Technology Limited (Alibaba Health), that] [2 ALIBABA GROUP HOLDING LIMITED]
EJ [E-HOUSE (CHINA)] SC 13E3: TABLE OF CONTENTS 3 Use these links to
[TABLE OF CONTENTS 3 Use these links to rapidly review the document E-House (China) Holdings Limited , 2016 Shareholders of E-House (China) Holdings Limited Re: Notice of Extraordinary General Meeting of Shareholders Dear Shareholder: You are cordially invited to attend an extraordinary general meeting of shareholders of E-House (China) Holdings Limited (the "Company") to be held on , 2016 at] [April 14, 2016 E-House (China) Holdings Limited Fairness Analysis Presented to the Special Committee of the Board of Directors The information contained herein is of a confidential nature and is intended for the use of the persons or firm to whom it is furnished by us. Reproduction, publication, or dissemination of portions hereof may not be made without prior approval] [SCHEDULE 13E-3 Rule 13e-3 Transaction Statement E-HOUSE (CHINA) HOLDINGS LIMITED (Name of the Issuer) E-House (China) Holdings Limited Neil Nanpeng Shen Xin Zhou SINA Corporation (Names of Persons Filing Statement) Ordinary Shares, par value $0.001 per share 26852W103* (CUSIP Number) E-House (China) Holding Limited Xin Zhou Neil Nanpeng Shen SINA Corporation (Name, Address and Telephone Number of Person Authorized to]
